Atorvastatin in Factorial with Omega-3 Fatty Acids Risk Reduction in Diabetes

Home page

The Atorvastatin in Factorial with Omega-3 fatty acids Risk Reduction in Diabetes (AFORRD) study was a one-year, community-based, multi-centre, randomised controlled trial assessing the degree to which a statin and/or omega-3 fatty acids reduce the estimated risk of coronary heart disease (CHD) in 1,000 people with Type 2 diabetes.

Principal Investigators: Professor Rury Holman and Professor Andrew Neil
Co-Investigator: Dr Andrew Farmer
Senior Project Manager: Lynne Tucker
Study Manager: Dr Lucielle Mansfield
ISRCTN number: 76737502

News

Show all

2006	December	The results of the AFORRD trial were presented at the International Diabetes Federation Congress in Cape Town on Thursday 7th December 2006
	August	Last Patient Last Visit
2005	July	AFORRD finished patient recruitment on 31st July 2005 and successfully randomised 800 participants.